Implementing a Single-Use TFF System in a cGMP Biomanufacturing Facility - This case study describes the process used to transition from a multi-use system to single-use tangential flow filtration for

ADVERTISEMENT

Implementing a Single-Use TFF System in a cGMP Biomanufacturing Facility
This case study describes the process used to transition from a multi-use system to single-use tangential flow filtration for performing final buffer exchange steps.


BioPharm International Supplements
Volume 25, Issue 11, pp. s20-s26

For a multiproduct cGMP manufacturing facility, measures to prevent risk of cross-contamination between products are a high priority. Single-use technology can provide a simple method of achieving this goal for many processing operations (1). This case study describes how the transition from multi-use to single-use tangential flow filtration (TFF) was evaluated and implemented for a buffer exchange step in a 500-L production-scale recombinant protein manufacturing facility (PF1) at CMC Biologics, a contract manufacturing organization (CMO).


Figure 1: Process flow diagrams. (A) A typical process flow for a monoclonal antibody or recombinant protein. Ultrafiltration and diafiltration (UF/DF) for buffer exchange is performed at the end of the manufacturing process for formulation of bulk drug substance. (B) Processing steps for UF/DF by tangential flow filtration (TFF). Steps that differ between re-useable and single-use filters are indicated on the right. Brackets on the left indicate processing times for pre- and post-use operations.
A typical monoclonal antibody (mAb) or recombinant protein manufacturing process uses ultrafiltration/diafiltration (UF/DF) by TFF for final product concentration and formulation of bulk drug substance (see Figure 1A). The primary criteria for such a TFF system are suitability for cGMP, product compatibility, and reliable performance, including high yield and efficient buffer exchange. Additional criteria of almost equal importance, particularly for a CMO, include rapid and predictable setup and operation, a platform system with multiple filter options to accommodate a wide range of protein products, and low total operating costs, including materials, labor, buffer usage, and overhead due to changeover between products. These last criteria are particularly well addressed by single-use technology. A primary objective of single-use systems is to simplify and reduce costs associated with product changeover, because cleaning and cleaning validation requirements are significantly reduced when product-contact surfaces are discarded after use. Additionally, for TFF, total operating time in routine usage is reduced through elimination of many of the steps required to clean and store membranes between manufacturing batches (see Figure 1B). As re-usable TFF membranes are typically product-dedicated, the significant logistics of storing and tracking multiple use TFF membranes for different protein products between manufacturing campaigns is completely eliminated by a single-use system. The economics of single-use TFF technology are also favorable relative to re-usable membranes for intermediate-scale manufacturing with relatively few batches in a campaign (2).

The PF1 cGMP manufacturing facility at CMC Biologics was designed for mammalian cell-culture processes up to 500-L production scale based on single-use technology. Typical PF1 clients have clinical-stage protein therapeutics with a need for relatively few (e.g., two to five) batches in a manufacturing campaign. Thus, between frequent needs for product changeover and favorable economics for short campaigns, a single-use TFF system was an obvious fit. However, to streamline facility commissioning, single-use technology was initially emphasized more heavily in upstream production and buffer preparation, allowing many of the downstream purification operations to leverage existing equipment and methodology from the re-useable systems already established in a parallel 3000-L production facility. Once the PF1 facility was in full operation, a strategic plan to transition multi-use operations to single use was implemented, with the final TFF buffer exchange step being one of the first to make the switch. The approach for transitioning was simple and straightforward. First, vendor descriptions were used to identify a TFF system which would best meet the needs of a CMO, and then performance was evaluated in three stages: 1) demonstrating suitability in scale-down models, 2) scale-up to a PF1 manufacturing process, and 3) assessing reliability over multiple runs with multiple lots of TFF filters.


blog comments powered by Disqus

ADVERTISEMENT

Moscow Hosts IFPMA Biosimilars Conference
May 17, 2013
AbbVie and Alvine Will Collaborate on Celiac Disease Therapy
May 15, 2013
FDA Issues Pharmacoepidemiologic Safety Study Guidance
May 14, 2013
USP Launches Initiative to Fight Counterfeit Drugs in Sub-Saharan Africa
May 13, 2013
Amgen Forms New Joint Venture to Commercialize Vectibix in China
May 13, 2013
Upcoming Conferences
UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

ADVERTISEMENT

Author Guidelines
FindPharma
Source: BioPharm International Supplements,
Click here